Celularity Inc Stock Price, News & Analysis

Welcome to our dedicated page for Celularity news (Ticker: CELUW), a resource for investors and traders seeking the latest updates and insights on Celularity stock.

Celularity Inc. (Nasdaq: CELU; warrants: CELUW) is frequently in the news as a regenerative and aging-related cellular medicine company focused on placenta-derived biomaterials and cell therapies. Its news flow covers developments across wound care, longevity-focused cell therapy, ophthalmic biologics, and corporate and capital markets activity. Readers following CELUW-related headlines can use this page to see how Celularity’s scientific, clinical, commercial, and financing updates intersect with the value of its listed warrants.

Company press releases highlight clinical milestones, such as publication of Phase 2 trial results for PDA-002, a placenta-derived mesenchymal stromal-like cell therapy evaluated in complex diabetic foot ulcers with peripheral artery disease. Other news items describe real-world evidence for Biovance human amniotic membrane allograft products in chronic wound healing, as well as the impact of Medicare coverage and payment policies on skin substitute products used in wound care.

Celularity also reports on strategic partnerships that extend its platform into new settings. Examples include a collaboration with Fountain Life to supply stem cell therapy products for use under a Florida statute governing stem cell therapies in orthopedics, wound care, and pain management, and an exclusive sublicense and manufacturing role for DefEYE, Inc. in ophthalmic biologics, including Biovance, Biovance 3L, Interfyl, and CentaFlex.

In addition, Celularity’s news includes financing transactions, balance sheet restructuring, and Nasdaq listing compliance updates, all of which can influence perceptions of risk and opportunity around CELU common stock and CELUW warrants. Investors and observers can use this news feed to monitor clinical data releases, reimbursement and regulatory developments, strategic alliances, and capital structure changes that the company discloses over time.